# Insulet Corporation – Consensus ‘buy’ rating and 24.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-consensus-buy-rating-and-24.3-upside-potential/4121133019
- Published: 2023-11-16T12:44:57+00:00
- Author: Charlotte Edwards

**Insulet Corporation** which can be found using ticker (PODD) have now 18 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $270.00 and $163.00 calculating the mean target
price we have $215.06. Given that the stocks previous close was at $172.95 and the
analysts are correct then there would likely be a percentage uptick in value of 
24.3%. The 50 day moving average now sits at $153.93 and the 200 day MA is $251.60.
The market cap for the company is 12.11B. The stock price for the company is currently
is currently $173.49 USD

 The potential market cap would be $15,064,012,357 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 100.87, revenue per share of $22.35
and a 2.36% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: